APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Acute Kidney Injury Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Acute Kidney Injury Drugs Market Outlook and Growth Opportunities 2026

Report ID 173960320422 December 2025192 pages

Choose your research edition.

Industry ResearchAcute Kidney Injury Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Kidney Injury Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Acute Kidney Injury Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Kidney Injury Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Kidney Injury Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Acute Kidney Injury Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Acute Kidney Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Kidney Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Kidney Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Acute Kidney Injury Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Acute Kidney Injury Drugs market include Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, Quark Pharmaceuticals, Baxter International, LG Chem, Asahi Kasei Medical and Angion Biomedica Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Acute Kidney Injury Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Kidney Injury Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Kidney Injury Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Acute Kidney Injury Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Acute Kidney Injury Drugs Segment by Company

Fresenius Medical Care AG & Co. KGaA

B. Braun Melsungen AG

Quark Pharmaceuticals

Baxter International

LG Chem

Asahi Kasei Medical

Angion Biomedica Corp

Acute Kidney Injury Drugs Segment by Type

Intrinsic Acute Kidney Injury

Postrenal Acute Kidney Injury

Prerenal Acute Kidney Injury

Others

Acute Kidney Injury Drugs Segment by Application

Hospital

Clinic

Acute Kidney Injury Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Acute Kidney Injury Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Acute Kidney Injury Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acute Kidney Injury Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Acute Kidney Injury Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Kidney Injury Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Kidney Injury Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Kidney Injury Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Acute Kidney Injury Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Kidney Injury Drugs industry.

Chapter 3: Detailed analysis of Acute Kidney Injury Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Acute Kidney Injury Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Acute Kidney Injury Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acute Kidney Injury Drugs Industry Trends Table 2. Acute Kidney Injury Drugs Industry Drivers Table 3. Acute Kidney Injury Drugs Industry Opportunities and Challenges Table 4. Acute Kidney Injury Drugs Industry Restraints Table 5. Global Acute Kidney Injury Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acute Kidney Injury Drugs Revenue Share by Company (2021-2026) Table 7. Global Acute Kidney Injury Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Acute Kidney Injury Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Acute Kidney Injury Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Acute Kidney Injury Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Acute Kidney Injury Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Acute Kidney Injury Drugs Company, Product Type & Application Table 13. Global Acute Kidney Injury Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Acute Kidney Injury Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Intrinsic Acute Kidney Injury Table 18. Significant Companies of Postrenal Acute Kidney Injury Table 19. Significant Companies of Prerenal Acute Kidney Injury Table 20. Significant Companies of Others Table 21. Global Acute Kidney Injury Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Acute Kidney Injury Drugs Sales Volume by Type (2021-2026) & (k units) Table 23. Global Acute Kidney Injury Drugs Sales Volume by Type (2027-2032) & (k units) Table 24. Global Acute Kidney Injury Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Acute Kidney Injury Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Acute Kidney Injury Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Acute Kidney Injury Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Acute Kidney Injury Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Acute Kidney Injury Drugs Sales Value Share by Type (2021-2026) Table 30. Global Acute Kidney Injury Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Global Acute Kidney Injury Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Acute Kidney Injury Drugs Sales Volume by Application (2021-2026) & (k units) Table 35. Global Acute Kidney Injury Drugs Sales Volume by Application (2027-2032) & (k units) Table 36. Global Acute Kidney Injury Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Acute Kidney Injury Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Acute Kidney Injury Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Acute Kidney Injury Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Acute Kidney Injury Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Acute Kidney Injury Drugs Sales Value Share by Application (2021-2026) Table 42. Global Acute Kidney Injury Drugs Sales Value Share by Application (2027-2032) Table 43. Global Acute Kidney Injury Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Acute Kidney Injury Drugs Sales by Region (2021-2026) & (k units) Table 45. Global Acute Kidney Injury Drugs Sales Market Share by Region (2021-2026) Table 46. Global Acute Kidney Injury Drugs Sales by Region (2027-2032) & (k units) Table 47. Global Acute Kidney Injury Drugs Sales Market Share by Region (2027-2032) Table 48. Global Acute Kidney Injury Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Acute Kidney Injury Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Acute Kidney Injury Drugs Sales Value Share by Region (2021-2026) Table 51. Global Acute Kidney Injury Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Acute Kidney Injury Drugs Sales Value Share by Region (2027-2032) Table 53. Global Acute Kidney Injury Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Acute Kidney Injury Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Acute Kidney Injury Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Acute Kidney Injury Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Acute Kidney Injury Drugs Sales by Country (2021-2026) & (k units) Table 58. Global Acute Kidney Injury Drugs Sales Market Share by Country (2021-2026) Table 59. Global Acute Kidney Injury Drugs Sales by Country (2027-2032) & (k units) Table 60. Global Acute Kidney Injury Drugs Sales Market Share by Country (2027-2032) Table 61. Global Acute Kidney Injury Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Acute Kidney Injury Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Acute Kidney Injury Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Acute Kidney Injury Drugs Sales Value Market Share by Country (2027-2032) Table 65. Fresenius Medical Care AG & Co. KGaA Company Information Table 66. Fresenius Medical Care AG & Co. KGaA Business Overview Table 67. Fresenius Medical Care AG & Co. KGaA Acute Kidney Injury Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Fresenius Medical Care AG & Co. KGaA Acute Kidney Injury Drugs Product Portfolio Table 69. Fresenius Medical Care AG & Co. KGaA Recent Development Table 70. B. Braun Melsungen AG Company Information Table 71. B. Braun Melsungen AG Business Overview Table 72. B. Braun Melsungen AG Acute Kidney Injury Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. B. Braun Melsungen AG Acute Kidney Injury Drugs Product Portfolio Table 74. B. Braun Melsungen AG Recent Development Table 75. Quark Pharmaceuticals Company Information Table 76. Quark Pharmaceuticals Business Overview Table 77. Quark Pharmaceuticals Acute Kidney Injury Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Quark Pharmaceuticals Acute Kidney Injury Drugs Product Portfolio Table 79. Quark Pharmaceuticals Recent Development Table 80. Baxter International Company Information Table 81. Baxter International Business Overview Table 82. Baxter International Acute Kidney Injury Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Baxter International Acute Kidney Injury Drugs Product Portfolio Table 84. Baxter International Recent Development Table 85. LG Chem Company Information Table 86. LG Chem Business Overview Table 87. LG Chem Acute Kidney Injury Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. LG Chem Acute Kidney Injury Drugs Product Portfolio Table 89. LG Chem Recent Development Table 90. Asahi Kasei Medical Company Information Table 91. Asahi Kasei Medical Business Overview Table 92. Asahi Kasei Medical Acute Kidney Injury Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Asahi Kasei Medical Acute Kidney Injury Drugs Product Portfolio Table 94. Asahi Kasei Medical Recent Development Table 95. Angion Biomedica Corp Company Information Table 96. Angion Biomedica Corp Business Overview Table 97. Angion Biomedica Corp Acute Kidney Injury Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Angion Biomedica Corp Acute Kidney Injury Drugs Product Portfolio Table 99. Angion Biomedica Corp Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Acute Kidney Injury Drugs Distributors List Table 103. Acute Kidney Injury Drugs Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Acute Kidney Injury Drugs Product Image Figure 2. Global Acute Kidney Injury Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Kidney Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Acute Kidney Injury Drugs Sales (2021-2032) & (k units) Figure 5. Global Acute Kidney Injury Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Acute Kidney Injury Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Intrinsic Acute Kidney Injury Image Figure 10. Postrenal Acute Kidney Injury Image Figure 11. Prerenal Acute Kidney Injury Image Figure 12. Others Image Figure 13. Global Acute Kidney Injury Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Acute Kidney Injury Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Acute Kidney Injury Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Acute Kidney Injury Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Acute Kidney Injury Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Acute Kidney Injury Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Global Acute Kidney Injury Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Acute Kidney Injury Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Acute Kidney Injury Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Acute Kidney Injury Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Acute Kidney Injury Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Acute Kidney Injury Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Acute Kidney Injury Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Acute Kidney Injury Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Acute Kidney Injury Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Acute Kidney Injury Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Acute Kidney Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Acute Kidney Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Acute Kidney Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Acute Kidney Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Acute Kidney Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Acute Kidney Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Acute Kidney Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Acute Kidney Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Acute Kidney Injury Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Acute Kidney Injury Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Acute Kidney Injury Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Acute Kidney Injury Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Intrinsic Acute Kidney Injury
  • Postrenal Acute Kidney Injury
  • Prerenal Acute Kidney Injury
  • Others
Applications
  • Hospital
  • Clinic
Companies covered
  • Fresenius Medical Care AG & Co. KGaA
  • B. Braun Melsungen AG
  • Quark Pharmaceuticals
  • Baxter International
  • LG Chem
  • Asahi Kasei Medical
  • Angion Biomedica Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Acute Kidney Injury Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Acute Kidney Injury Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Acute Kidney Injury Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Acute Kidney Injury Drugs Market Dynamics
  1. 2.1 Acute Kidney Injury Drugs Industry Trends
  2. 2.2 Acute Kidney Injury Drugs Industry Drivers
  3. 2.3 Acute Kidney Injury Drugs Industry Opportunities and Challenges
  4. 2.4 Acute Kidney Injury Drugs Industry Restraints
3 Acute Kidney Injury Drugs Market by Company
  1. 3.1 Global Acute Kidney Injury Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Acute Kidney Injury Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Acute Kidney Injury Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Acute Kidney Injury Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Acute Kidney Injury Drugs Company Ranking (2024-2026)
  6. 3.6 Global Acute Kidney Injury Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Acute Kidney Injury Drugs Company Product Type and Application
  8. 3.8 Global Acute Kidney Injury Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Acute Kidney Injury Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Acute Kidney Injury Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Acute Kidney Injury Drugs Market by Type
  1. 4.1 Acute Kidney Injury Drugs Type Introduction
  2. 4.1.1 Intrinsic Acute Kidney Injury
  3. 4.1.2 Postrenal Acute Kidney Injury
  4. 4.1.3 Prerenal Acute Kidney Injury
  5. 4.1.4 Others
  6. 4.2 Global Acute Kidney Injury Drugs Sales Volume by Type
  7. 4.2.1 Global Acute Kidney Injury Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Acute Kidney Injury Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Acute Kidney Injury Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Acute Kidney Injury Drugs Sales Value by Type
  11. 4.3.1 Global Acute Kidney Injury Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Acute Kidney Injury Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Acute Kidney Injury Drugs Sales Value Share by Type (2021-2032)
5 Acute Kidney Injury Drugs Market by Application
  1. 5.1 Acute Kidney Injury Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Acute Kidney Injury Drugs Sales Volume by Application
  5. 5.2.1 Global Acute Kidney Injury Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Acute Kidney Injury Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Acute Kidney Injury Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Acute Kidney Injury Drugs Sales Value by Application
  9. 5.3.1 Global Acute Kidney Injury Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Acute Kidney Injury Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Acute Kidney Injury Drugs Sales Value Share by Application (2021-2032)
6 Acute Kidney Injury Drugs Regional Sales and Value Analysis
  1. 6.1 Global Acute Kidney Injury Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Kidney Injury Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Acute Kidney Injury Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Acute Kidney Injury Drugs Sales by Region (2027-2032)
  5. 6.3 Global Acute Kidney Injury Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Acute Kidney Injury Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Acute Kidney Injury Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Acute Kidney Injury Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Acute Kidney Injury Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Acute Kidney Injury Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Acute Kidney Injury Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Acute Kidney Injury Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Acute Kidney Injury Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Acute Kidney Injury Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Acute Kidney Injury Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Acute Kidney Injury Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Acute Kidney Injury Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Acute Kidney Injury Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Acute Kidney Injury Drugs Sales Value Share by Country, 2025 VS 2032
7 Acute Kidney Injury Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Acute Kidney Injury Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acute Kidney Injury Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Acute Kidney Injury Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Acute Kidney Injury Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Acute Kidney Injury Drugs Sales by Country (2027-2032)
  6. 7.4 Global Acute Kidney Injury Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Acute Kidney Injury Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Acute Kidney Injury Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Acute Kidney Injury Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Acute Kidney Injury Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Acute Kidney Injury Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Fresenius Medical Care AG & Co. KGaA
  2. 8.1.1 Fresenius Medical Care AG & Co. KGaA Company Information
  3. 8.1.2 Fresenius Medical Care AG & Co. KGaA Business Overview
  4. 8.1.3 Fresenius Medical Care AG & Co. KGaA Acute Kidney Injury Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Fresenius Medical Care AG & Co. KGaA Acute Kidney Injury Drugs Product Portfolio
  6. 8.1.5 Fresenius Medical Care AG & Co. KGaA Recent Developments
  7. 8.2 B. Braun Melsungen AG
  8. 8.2.1 B. Braun Melsungen AG Company Information
  9. 8.2.2 B. Braun Melsungen AG Business Overview
  10. 8.2.3 B. Braun Melsungen AG Acute Kidney Injury Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 B. Braun Melsungen AG Acute Kidney Injury Drugs Product Portfolio
  12. 8.2.5 B. Braun Melsungen AG Recent Developments
  13. 8.3 Quark Pharmaceuticals
  14. 8.3.1 Quark Pharmaceuticals Company Information
  15. 8.3.2 Quark Pharmaceuticals Business Overview
  16. 8.3.3 Quark Pharmaceuticals Acute Kidney Injury Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Quark Pharmaceuticals Acute Kidney Injury Drugs Product Portfolio
  18. 8.3.5 Quark Pharmaceuticals Recent Developments
  19. 8.4 Baxter International
  20. 8.4.1 Baxter International Company Information
  21. 8.4.2 Baxter International Business Overview
  22. 8.4.3 Baxter International Acute Kidney Injury Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Baxter International Acute Kidney Injury Drugs Product Portfolio
  24. 8.4.5 Baxter International Recent Developments
  25. 8.5 LG Chem
  26. 8.5.1 LG Chem Company Information
  27. 8.5.2 LG Chem Business Overview
  28. 8.5.3 LG Chem Acute Kidney Injury Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 LG Chem Acute Kidney Injury Drugs Product Portfolio
  30. 8.5.5 LG Chem Recent Developments
  31. 8.6 Asahi Kasei Medical
  32. 8.6.1 Asahi Kasei Medical Company Information
  33. 8.6.2 Asahi Kasei Medical Business Overview
  34. 8.6.3 Asahi Kasei Medical Acute Kidney Injury Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Asahi Kasei Medical Acute Kidney Injury Drugs Product Portfolio
  36. 8.6.5 Asahi Kasei Medical Recent Developments
  37. 8.7 Angion Biomedica Corp
  38. 8.7.1 Angion Biomedica Corp Company Information
  39. 8.7.2 Angion Biomedica Corp Business Overview
  40. 8.7.3 Angion Biomedica Corp Acute Kidney Injury Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Angion Biomedica Corp Acute Kidney Injury Drugs Product Portfolio
  42. 8.7.5 Angion Biomedica Corp Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Acute Kidney Injury Drugs Value Chain Analysis
  2. 9.1.1 Acute Kidney Injury Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Acute Kidney Injury Drugs Sales Mode & Process
  6. 9.2 Acute Kidney Injury Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Acute Kidney Injury Drugs Distributors
  9. 9.2.3 Acute Kidney Injury Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst